Insider · CIK 0001866174
Colin Walsh
Files at ATTO (Attovia Therapeutics, Inc.). First filing Aug 13, 2026, latest Aug 28, 2026.
In brief
Colin Walsh files SEC Form 4 as director at ATTO (Attovia Therapeutics, Inc.). Since Aug 13, 2026, Colin Walsh has reported 2 open-market buys worth $21M and 2 open-market sells worth $4.5M, the latest filed on Aug 28, 2026.
A track record needs three past buys with six months of prices behind them; Colin Walsh has 0, so none is measured yet.
The newest scored trade: bought $10M of ATTO on Aug 5, 2026, filed Aug 28, 2026, scored 63 (notable). In the last 12 months: 2 buys worth $21M and 2 sells worth $4.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ATTO: Attovia Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 63Notable | Attovia Therapeutics, Inc. | $10M 585,000 shares | - | - | |
| 68Notable | Attovia Therapeutics, Inc. | $2.3M 105,807 shares | -124% | - | |
| 63Notable | Attovia Therapeutics, Inc. | $10M 585,000 shares | - | - | |
| 68Notable | Attovia Therapeutics, Inc. | $2.3M 105,807 shares | -124% | - |
Transactions
The newest 50 of 64 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +85,000 | $21.00 | $1.8M | 85,000 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -988 | $22.03 | $22k | 84,012 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -447 | $21.87 | $9,776 | 83,565 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,332 | $22.03 | $29k | 82,233 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 82,033 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,556 | $22.06 | $34k | 80,477 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,402 | $22.02 | $75k | 77,075 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.10 | $4,420 | 76,875 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -480 | $21.55 | $10k | 76,395 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $22.11 | $2,211 | 76,295 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -753 | $21.97 | $17k | 75,542 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -672 | $22.02 | $15k | 74,870 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,970 | $22.03 | $154k | 67,900 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -400 | $22.02 | $8,808 | 67,500 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,180 | $21.84 | $26k | 66,320 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,040 | $22.05 | $23k | 65,280 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -300 | $20.84 | $6,252 | 64,980 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -443 | $21.78 | $9,649 | 64,537 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 64,337 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -700 | $22.07 | $15k | 63,637 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,163 | $22.19 | $26k | 62,474 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $21.99 | $2,199 | 62,374 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,763 | $21.61 | $146k | 55,611 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -76,418 | $21.04 | $1.6M | 0 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stockindirect: See Footnotes | +1,957,134 | $0.00 | $0 | 2,042,134 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Common Stockindirect: See Footnotes | +478,498 | $0.00 | $0 | 2,520,632 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +500,000 | $17.00 | $8.5M | 3,020,632 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnotes | -18,181,830 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | CConversion Series C Preferred Stockderivativeindirect: See Footnotes | -4,445,275 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +2,872 | $21.22 | $61k | 2,872 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +28,717 | $21.22 | $609k | 31,589 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,488 | $21.22 | $244k | 43,077 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +45,588 | $21.27 | $970k | 88,665 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +11,398 | $21.27 | $242k | 100,063 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Equity Swapderivativeindirect: See Footnotes | +5,744 | $21.22 | $122k | 105,807 | Aug 28, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | POpen-market purchase Common Stockindirect: See Footnotes | +85,000 | $21.00 | $1.8M | 85,000 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -988 | $22.03 | $22k | 84,012 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -447 | $21.87 | $9,776 | 83,565 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,332 | $22.03 | $29k | 82,233 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.05 | $4,410 | 82,033 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,556 | $22.06 | $34k | 80,477 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -3,402 | $22.02 | $75k | 77,075 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -200 | $22.10 | $4,420 | 76,875 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -480 | $21.55 | $10k | 76,395 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -100 | $22.11 | $2,211 | 76,295 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -753 | $21.97 | $17k | 75,542 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -672 | $22.02 | $15k | 74,870 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -6,970 | $22.03 | $154k | 67,900 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -400 | $22.02 | $8,808 | 67,500 | Aug 13, 2026 |
| Aug 5, 2026 | ATTO Attovia Therapeutics, Inc. | SOpen-market sale Common Stockindirect: See Footnotes | -1,180 | $21.84 | $26k | 66,320 | Aug 13, 2026 |
Questions about Colin Walsh
Answered from the filings on this page, as of the latest one.
Is Colin Walsh buying or selling?
In the last 12 months Colin Walsh reported 2 open-market buys worth $21M and 2 open-market sells worth $4.5M on SEC Form 4; the latest was bought $10M of ATTO on Aug 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Colin Walsh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Colin Walsh has 0.
Where does Colin Walsh file Form 4?
Colin Walsh has filed Form 4 at ATTO (Attovia Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.